Modulating Bacteroides to boost anti-PD-1 immunotherapy in HCC
Journal for ImmunoTherapy of Cancer · 2026-02 · 14 (2) · e013755
DOI: 10.1136/jitc-2025-013755 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 17.02.2026. Verfasst von Xiaoqiang Qi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, University of Missouri, Columbia, Missouri, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bacteroides, Immunotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
The gut microbiota is increasingly recognized as a critical external regulator along the gut-liver axis, influencing hepatocarcinogenesis and modulating responses to immunotherapy. However, the specific microbial determinants, underlying mechanisms, and potential clinical applications remain incompletely elucidated.
Methods
Building on the observed association between gut microbiota and anti-programmed cell death protein-1 (PD-1) immunotherapeutic efficacy in patients with hepatocellular carcinoma (HCC), we leveraged a suite of clinically relevant murine HCC models to comprehensively characterize tumor-associated microbial signatures using 16S ribosomal RNA gene sequencing. By precisely manipulating microbial composition through a non-hepatotoxic antibiotic cocktail 3 (ABX-3), targeted microbial supplementation, human fecal microbiota transplant (FMT), and controlled Bacteroides thetaiotaomicron (B.th ) repopulation following gut sterilization with ABX-5, we demonstrated a direct causal relationship between microbiota modulation and intrahepatic immune activation. Single-cell RNA sequencing of hepatic non-parenchymal cells, together with functional validation experiments, was performed to elucidate the underlying immune mechanisms.
Results
Bacteroides -enriched gut microbiota derived from anti-PD-1-responsive patients with HCC significantly suppressed tumor growth in murine HCC models. In parallel, within our murine HCC system, ABX-3 administration, implemented as both a preventive and therapeutic intervention, attenuated tumor initiation and progression by selectively enriching Bacteroides within the gut microbial community. Functionally, ABX-3 enhanced the capacity of tumor antigen-specific T-cell receptor-I T cells to mount robust immune responses, culminating in targeted tumor regression following antigen-specific immunization. Among the Bacteroides species, B.th emerged as a critical mediator that potentiated αPD-1 immunotherapy in HCC by relieving Krüppel-like factor 2 (KLF2)-dependent suppression in dendritic cells (DCs). Mechanistically, the KLF2–toll-like receptor 9 (TLR9) signaling axis in DCs governed the activation of antigen-specific CD8 + T cells, thereby amplifying antitumor immunity within the HCC microenvironment.
Conclusions
B.th is identified as a key immunomodulatory species that enhances anti-PD-1 efficacy by reprogramming DCs through the KLF2/TLR9 signaling pathway. These findings reveal a novel microbiota-informed strategy to improve immunotherapeutic outcomes in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, University of Missouri, Columbia, Missouri, USA.
- Department of Surgery, UConn Health Center, Farmington, Connecticut, USA.
- Department of Radiology, University of Missouri, Columbia, Missouri, USA.
- Harry S. Truman Memorial VA Hospital, Columbia, Missouri, USA.
- Department of Veterinary Pathobiology, University of Missouri, Columbia, Missouri, USA.
- Department of Surgery, University of Missouri, Columbia, Missouri, USA gli@uchc.edu ksoc@uchc.edu.
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
- U.S. Department of Veterans Affairs
Zitieren
APA
Qi, X., Yang, M., Liu, X., Ma, L., Kaifi, J. T., Ericsson, A. C., Kimchi, E. T., Staveley-O'Carroll, K. F., & Li, G. (2026). Modulating Bacteroides to boost anti-PD-1 immunotherapy in HCC. Journal for ImmunoTherapy of Cancer, 14(2), e013755. https://doi.org/10.1136/jitc-2025-013755
Vancouver
Qi X, Yang M, Liu X, Ma L, Kaifi JT, Ericsson AC, et al. Modulating Bacteroides to boost anti-PD-1 immunotherapy in HCC. Journal for ImmunoTherapy of Cancer. 2026;14(2):e013755. doi:10.1136/jitc-2025-013755
BibTeX
@article{Qi2026,
author = {Qi, Xiaoqiang and Yang, Ming and Liu, Xinjian and Ma, Lixin and Kaifi, Jussuf T and Ericsson, Aaron C and Kimchi, Eric T and Staveley-O'Carroll, Kevin F and Li, Guangfu},
title = {Modulating Bacteroides to boost anti-PD-1 immunotherapy in HCC},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {2},
pages = {e013755},
doi = {10.1136/jitc-2025-013755}
}
EUVIMED